KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesAsset Writedowns and ImpairmentCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in InventoryChange in ReceivablesDepreciation & Amortization (CF)Exchange Rate EffectFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeOther Working Capital ChangesOther financing activitiesShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Nektar Therapeutics (NKTR) Change in Receivables (2016 - 2024)

Nektar Therapeutics (NKTR) has 15 years of Change in Receivables data on record, last reported at $2.2 million in Q4 2024.

  • For Q4 2024, Change in Receivables rose 320.62% year-over-year to $2.2 million; the TTM value through Sep 2025 reached $2.2 million, up 1494.94%, while the annual FY2024 figure was $3.0 million, 163.76% up from the prior year.
  • Change in Receivables reached $2.2 million in Q4 2024 per NKTR's latest filing, up from $850000.0 in the prior quarter.
  • Across five years, Change in Receivables topped out at $7.7 million in Q1 2022 and bottomed at -$20.2 million in Q2 2022.
  • Average Change in Receivables over 5 years is -$1.6 million, with a median of -$642000.0 recorded in 2021.
  • Peak YoY movement for Change in Receivables: soared 1739.18% in 2020, then tumbled 6992.63% in 2022.
  • A 5-year view of Change in Receivables shows it stood at -$8.0 million in 2020, then skyrocketed by 68.87% to -$2.5 million in 2021, then crashed by 121.86% to -$5.6 million in 2022, then soared by 82.0% to -$999000.0 in 2023, then skyrocketed by 320.62% to $2.2 million in 2024.
  • Per Business Quant database, its latest 3 readings for Change in Receivables were $2.2 million in Q4 2024, $850000.0 in Q3 2024, and -$2.4 million in Q2 2024.